Suppression of Ocular Scarring by RNA Interference
About the Research Project
Program
Award Type
Standard
Award Amount
$90,000
Active Dates
April 01, 2006 - March 31, 2009
Grant ID
G2006014
Goals
This project proposes to employ RNA interference (RNAi) technology to target CTGF. It is hoped that silencing of the growth factor will help block the scarring action. The efficacy and consequence of the siRNAs will be studied in cultured conjunctival fibroblasts.
Summary
Connective tissue growth factor (CTGF) is an important mediator of wound healing in various tissues. In the eye, CTGF has been implicated in corneal wound healing, and subconjunctival scarring following glaucoma surgery. Investigation in an ocular inflammation/fibrosis model in mouse will be followed to determine whether downregulation of CTGF would reduce inflammation and scarring. The current proposal is highly significant for its clinical impact since excessive scarring is often a major cause of impaired vision and blindness. Results obtained from this application may lead to novel therapeutic modalities to prevent inflammation and scarring after glaucoma surgery and in eye diseases including corneal opacities.
Related Grants
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
National Glaucoma Research
Role of a Key Gene, Angptl7, in Steroid-Induced Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dan Stamer, PhD
Current Organization
Arizona Board of Regents, University of Arizona
Role of a Key Gene, Angptl7, in Steroid-Induced Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dan Stamer, PhD
Current Organization
Arizona Board of Regents, University of Arizona
National Glaucoma Research
Enhancing Access to Glaucoma Care Using Artificial Intelligence
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Benjamin Xu, MD, PhD
Current Organization
University of Southern California
Enhancing Access to Glaucoma Care Using Artificial Intelligence
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Benjamin Xu, MD, PhD
Current Organization
University of Southern California